Abstract:Background Adoptive cell therapy (ACT) has shown great promise as a cancer therapeutic in some hematologic malignancies. However, several barriers prevent widespread use of cellular therapies in other cancers, including the need for T cells to perform and persist within the nutrient-poor tumor microenvironment (TME). Extensive in vitro culture is required for all current forms of ACT, but current culture strategies favor the energetic needs of T cells for rapid and robust expansion while ignoring their metabolic requirements within the TME. Here we demonstrate that the deleterious effects of in vitro culture can be mitigated by redirecting T cell glycolysis away from terminal lactate production to more energetically efficient OXPHOS during initial expansion. This in vitro metabolic shift drastically improves anti-tumor efficacy in vivo and establishes long-term memory without any further modifications, thus demonstrating an easily applied improvement for all forms of ACT. Methods Antigen-specific T cells were activated in culture with their cognate peptide or in vivo in response to cognate antigen. The pyruvate dehydrogenase kinase (PDHK1) inhibitor dichloroacetate (DCA) was used to redirect glucose flux during cell expansion. Mouse experiments were performed with gp100-specific pmel-1 TCR-Tg T cells transferred into B16 melanoma-bearing mice. Human experiments were performed with anti-hCD19 CAR-T cells transferred into NSG mice bearing hCD19-A549 lung cancer cells. Results Identical, antigen-specific T cells stimulated with typical in vitro culture conditions or responding to cognate antigen in vivo differ not in effector function but heavily in their metabolism: typical T cell activation and culture heavily favors aerobic glycolysis. The PDHK1 inhibitor DCA allows for glucose uptake and metabolism but shunts glucose into the mitochondria, maintaining mitochondrial health. In vitro expansion of T cells in the presence of DCA improves their pre-infusion metabolic profile, cytokine production, and survival in low nutrient culture media. Expansion in the presence of DCA results in striking improvements in ACT in both murine TCR-Tg and human CAR-T cells. Conclusions Current culture strategies do not prepare T cells for performance within the TME. DCA shunts glycolysis in a manner that re-directs metabolism to a more oxidative state. This small redirection improves the phenotype of T cells pre-infusion and better prepares them for the lack of nutrients in vivo. By generating more functional T cells for infusion, we are able to metabolically enhance their in vivo performance in a manner potentially synergistic with other more engineered improvements.

Improving the metabolic fidelity of cancer models with a physiological cell culture medium

Rational cell culture optimization enhances experimental reproducibility in cancer cells

Tumour Microenvironment-Like Conditions Alter Pancreatic Cancer Cell Metabolism and Behaviour

Understanding natural isotopic variations in cultured cancer cells

Large-Scale Modeling Approach Reveals Functional Metabolic Shifts during Hepatic Differentiation

Stiffer-Matrix-Induced PGC-1α Upregulation Enhanced Mitochondrial Biogenesis and Oxidative Stress Resistance in Non-small Cell Lung Cancer.

Metabolic Constants and Plasticity of Cancer Cells in a Limiting Glucose and Glutamine Microenvironment—A Pyruvate Perspective

Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs

Integrating a dynamic central metabolism model of cancer cells with a hybrid 3D multiscale model for vascular hepatocellular carcinoma growth

3D Modeling: Insights into the Metabolic Reprogramming of Cholangiocarcinoma Cells

Modelling and deciphering tumour metabolism in CRISPR screens

Stable isotope-resolved metabolomics analyses of metabolic phenotypes reveal variable glutamine metabolism in different patient-derived models of non-small cell lung cancer from a single patient

Assessment and process optimization of high throughput biofabrication of immunocompetent breast cancer model for drug screening applications

Metastatic Breast Cancer Cells are Metabolically Reprogrammed to Maintain Redox Homeostasis during Metastasis.

Identifying strategies to target the metabolic flexibility of tumours

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines

Developing high-fidelity hepatotoxicity models from pluripotent stem cells

Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism

Cultivation of Cells in a Physiological Plasmax Medium Increases Mitochondrial Respiratory Capacity and Reduces Replication Levels of RNA Viruses

Enhancing Maturation and Translatability of Human Pluripotent Stem Cell-Derived Cardiomyocytes through a Novel Medium Containing Acetyl-CoA Carboxylase 2 Inhibitor

100 Redirecting glucose flux during in vitro expansion improves the in vivo performance of adoptive T cell therapies for cancer